These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 2422492)

  • 21. Clinical pharmacology of inodilators.
    Dei Cas L; Metra M; Visioli O
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S60-71. PubMed ID: 2483442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neurohormonal factors in heart failure (and III)].
    Cosín Aguilar J; Cruz Fernández JM; de Teresa Galván E; Ferreira Montero IJ; López-Sendón J; Soler Soler J; Tamargo Menéndez J
    Rev Esp Cardiol; 1996 Jun; 49(6):405-22. PubMed ID: 8753906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of congestive heart failure: neuroendocrine approach.
    Shmuely H; Sclarovsky S; Rosenfeld JB
    Isr J Med Sci; 1993 Jan; 29(1):6-10. PubMed ID: 8454456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure.
    Hülsmann M; Stanek B; Frey B; Berger R; Rödler S; Siegel A; Hartter E; Schuller M; Ogris E; Pacher R
    J Heart Lung Transplant; 1997 May; 16(5):556-62. PubMed ID: 9171275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathophysiology and therapy of heart failure, new insights and developments. Part II. Cardiac and peripheral alterations during progressive heart failure.
    Remme WJ
    Neth J Med; 1993 Oct; 43(3-4):125-46. PubMed ID: 8302392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New inotropic agents in the treatment of congestive heart failure].
    Freitas M
    Rev Port Cardiol; 1993 Nov; 12 Suppl 4():19-28, 7-8. PubMed ID: 7904458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
    Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
    J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemistry and pathophysiology of congestive heart failure: is there a role for magnesium?
    Altura BM; Altura BT
    Magnesium; 1986; 5(3-4):134-43. PubMed ID: 3523055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chronic left heart ventricle failure and inotropic stimulation].
    Myhre ES; Gundersen T; Dickstein K; Hole T; Kjekshus J; Rønnevik P; Smith P; Westheim A
    Tidsskr Nor Laegeforen; 1995 Jan; 115(3):360-4. PubMed ID: 7855836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New positive inotropic substances--true inotropy or peripheral effects?
    Wilmshurst P
    Z Kardiol; 1988; 77 Suppl 5():103-11. PubMed ID: 3066033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Congestive heart failure. Drug therapy: central or peripheral approach?
    Remme WJ
    Cardiologia; 1993 Dec; 38(12 Suppl 1):51-9. PubMed ID: 7912652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Drug therapy of heart failure].
    Follath F
    Ther Umsch; 1993 Jun; 50(6):425-33. PubMed ID: 8351674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review: therapeutic concepts of congestive heart failure.
    Haustein KO
    Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):273-81. PubMed ID: 1974888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neurohormonal factors in heart failure. I].
    Cosín Aguilar J; Cruz Fernández JM; de Teresa Galván E; Ferreira Montero IJ; López-Sendón J; Soler Soler J; Tamargo Menéndez J
    Rev Esp Cardiol; 1996 Apr; 49(4):239-52. PubMed ID: 8650399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of congestive heart failure: is the role of positive inotropic therapy fading?
    Futterman LG; Lemberg L
    Am J Crit Care; 1996 Nov; 5(6):455-60. PubMed ID: 8922162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined angiotensin-converting enzyme inhibition and adrenomedullin in an ovine model of heart failure.
    Rademaker MT; Charles CJ; Cooper GJ; Coy DH; Espiner EA; Lewis LK; Nicholls MG; Richards AM
    Clin Sci (Lond); 2002 Jun; 102(6):653-60. PubMed ID: 12049620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Congestive heart failure: pathophysiology and management with special reference to systemic hypertension.
    Visser FC
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S8-11. PubMed ID: 1721986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The physiopathological aspects and new therapeutic approaches in cardiac-circulatory failure].
    Peruzzi G; Di Nardo P; Raimondi G; Legramante JM; Iellamo F; Massaro M; Bellegrandi F; Minieri M; Pafi M; Castrucci F
    Clin Ter; 1992 Nov; 141(11):339-72. PubMed ID: 1493659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical aspects of differential drug therapy of chronic heart failure].
    Erdmann E; Beuckelmann D; Böhm M; Schwinger HG
    Z Kardiol; 1992; 81 Suppl 4():97-103. PubMed ID: 1290310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.